Zydus gets USFDA approval for Levothyroxine Sodium for Injection

Zydus Lifesciences Limited on Tuesday has received final approval from the United States Food and Drug Administration (USFDA) for Levothyroxine Sodium for Injection 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial.

Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma, the company informed to the stock exchange.

Further, the drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).

The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04, the company said.

On Tuesday, at around 10:30 AM, Zydus Lifesciences was trading at Rs482.10 per share lower by 0.04% on the BSE.

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Candlestick Patterns

blog-logo

11 mins read . 03 Oct 2024

Ascending Triangle Pattern - Definition, Tips, Component & How to Trade

  • 0 people read
blog-logo

IPO

blog-logo

5 mins read . 19 Sep 2024

Vision Infra Equipment Solutions Limited IPO

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions